News
6h
Investor's Business Daily on MSNThe Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent.'Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety ...
Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...
Teijin Automotive Technologies has announced its name: CSP. This rebranding, effective July 1, 2025, marks the company’s ...
Shares of healthcare products company West Pharmaceutical Services (NYSE:WST) jumped 22.9% in the afternoon session after the ...
As gene therapy maker Sarepta Therapeutics tangles with FDA over its Duchenne treatment, patients and their families are ...
According to Endpoints News, FDA officials stated that the Center for Biologics Evaluation and Research (CBER) review staff are "unanimous" that Elevidys should never return to market. The report ...
Explore more
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...
The top financial leader at Thermo Fisher Scientific Inc. plans to retire from the company in 2026 after more than a decade ...
We recently published 12 Stocks Jim Cramer Discussed As Analyzed Morgan Stanley’s Comments. Sarepta Therapeutics, Inc.
Swiss pharma giant Roche has paused shipments of the gene therapy Elevidys (delandistrogene moxeparvovec) for new orders in certain countries outside the USA.
Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results